These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21979923)

  • 1. Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients.
    Paulzen M; Finkelmeyer A; Grözinger M
    Pharmacopsychiatry; 2011 Nov; 44(7):317-23. PubMed ID: 21979923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.
    Lobo ED; Bergstrom RF; Reddy S; Quinlan T; Chappell J; Hong Q; Ring B; Knadler MP
    Clin Pharmacokinet; 2008; 47(3):191-202. PubMed ID: 18307373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine: clinical pharmacokinetics and drug interactions.
    Knadler MP; Lobo E; Chappell J; Bergstrom R
    Clin Pharmacokinet; 2011 May; 50(5):281-94. PubMed ID: 21366359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy.
    Miljković BR; Pokrajac M; Timotijević I; Varagić V
    Int Clin Psychopharmacol; 1997 Jul; 12(4):207-12. PubMed ID: 9347381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.
    Conus P; Bondolfi G; Eap CB; Macciardi F; Baumann P
    Pharmacopsychiatry; 1996 May; 29(3):108-10. PubMed ID: 8738315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
    Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
    J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of the pharmacokinetics of fluvoxamine.
    van Harten J
    Clin Pharmacokinet; 1995; 29 Suppl 1():1-9. PubMed ID: 8846617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients.
    Spina E; Pollicino AM; Avenoso A; Campo GM; Caputi AP
    Int J Clin Pharmacol Res; 1993; 13(3):167-71. PubMed ID: 8225700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
    DeVane CL; Gill HS
    J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey.
    Waldschmitt C; Vogel F; Pfuhlmann B; Hiemke C
    Pharmacopsychiatry; 2009 Sep; 42(5):189-93. PubMed ID: 19724981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.
    Vezmar S; Miljkovic B; Vucicevic K; Timotijevic I; Prostran M; Todorovic Z; Pokrajac M
    J Pharmacol Sci; 2009 May; 110(1):98-104. PubMed ID: 19444001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between fluvoxamine and cotinine or caffeine.
    Yoshimura R; Ueda N; Nakamura J; Eto S; Matsushita M
    Neuropsychobiology; 2002; 45(1):32-5. PubMed ID: 11803239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients.
    Suzuki Y; Sawamura K; Someya T
    Neuropsychopharmacology; 2006 Apr; 31(4):825-31. PubMed ID: 16205777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
    Patroneva A; Connolly SM; Fatato P; Pedersen R; Jiang Q; Paul J; Guico-Pabia C; Isler JA; Burczynski ME; Nichols AI
    Drug Metab Dispos; 2008 Dec; 36(12):2484-91. PubMed ID: 18809731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of the newest antidepressants: comparisons with related predecessors.
    Caccia S
    IDrugs; 2004 Feb; 7(2):143-50. PubMed ID: 15057659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold.
    Anttila AK; Rasanen L; Leinonen EV
    Ann Pharmacother; 2001 Oct; 35(10):1221-3. PubMed ID: 11675851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience.
    Hochberg HM; Kanter D; Houser VP
    Pharmacopsychiatry; 1995 Nov; 28(6):253-6. PubMed ID: 8773292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.